[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2007110230A3 - Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections - Google Patents

Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections Download PDF

Info

Publication number
WO2007110230A3
WO2007110230A3 PCT/EP2007/002699 EP2007002699W WO2007110230A3 WO 2007110230 A3 WO2007110230 A3 WO 2007110230A3 EP 2007002699 W EP2007002699 W EP 2007002699W WO 2007110230 A3 WO2007110230 A3 WO 2007110230A3
Authority
WO
WIPO (PCT)
Prior art keywords
spp1
disease
mammal
level
diseases
Prior art date
Application number
PCT/EP2007/002699
Other languages
French (fr)
Other versions
WO2007110230A2 (en
Inventor
Evie Melanitou-Mcclymont
Original Assignee
Pasteur Institut
Evie Melanitou-Mcclymont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/389,261 external-priority patent/US20070224638A1/en
Priority claimed from EP06290485A external-priority patent/EP1840573A1/en
Application filed by Pasteur Institut, Evie Melanitou-Mcclymont filed Critical Pasteur Institut
Publication of WO2007110230A2 publication Critical patent/WO2007110230A2/en
Publication of WO2007110230A3 publication Critical patent/WO2007110230A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a method for the early diagnosis of a disease having a pre-inflammatory phase, or for the diagnosis of a predisposition to said disease, in a mammal, prior to any clinical signs, comprising measuring the level of at least a marker protein chosen amongst the following murine proteins Pap, Reg3a, Reg2, Cel, Reg1, Tff2, Clps, Spp1, Klk9, Klk6, Rib1, Klk5, Muc1, Cckar, Ggh, Ang, Nucb2, Pnliprp2, Pla2g1b, Ela1 Ela2, 2210010C04Rik, Pnliprpi, ltmap1, Vtn, C1qb, Sycn, Amy1, Ctrb1, 1110002O23Rik, 1810014L12Rik and their respective mammalian orthologs, in a body fluid or tissue sample obtained from said mammal, comparing the measured level to a reference level for said marker protein and diagnosing the later onset of said disease if the measured level is significantly superior to the reference level. The invention also encompasses related methods and uses of these early markers of diseases having a pre-inflammatory phase. A preferred mammal is human and preferred diseases are auto-immune diseases, especially type 1 diabetes. A preferred protein is the murine spp1 or its human ortholog osteopontin or another mammalian ortholog of spp1.
PCT/EP2007/002699 2006-03-27 2007-03-27 Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections WO2007110230A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/389,261 US20070224638A1 (en) 2006-03-27 2006-03-27 Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
EP06290485.9 2006-03-27
EP06290485A EP1840573A1 (en) 2006-03-27 2006-03-27 Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
US11/389,261 2006-03-27

Publications (2)

Publication Number Publication Date
WO2007110230A2 WO2007110230A2 (en) 2007-10-04
WO2007110230A3 true WO2007110230A3 (en) 2007-12-06

Family

ID=38265132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/002699 WO2007110230A2 (en) 2006-03-27 2007-03-27 Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections

Country Status (1)

Country Link
WO (1) WO2007110230A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884073B2 (en) 2004-11-04 2011-02-08 Hanall Biopharma Co., Ltd. Modified growth hormone
US8052964B2 (en) 2002-09-09 2011-11-08 Hanall Biopharma Co., Ltd. Interferon-β mutants with increased anti-proliferative activity

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008022609B4 (en) * 2008-05-05 2011-07-28 Otto-von-Guericke-Universität Magdeburg Medizinische Fakultät, 39120 Method for detecting the presence of kidney stones and / or inflammation of the urinary tract
WO2010085879A1 (en) * 2009-01-28 2010-08-05 Industrial Technology Research Institute Urine and serum biomarkers associated with diabetic nephropathy
JP2014502258A (en) 2010-10-22 2014-01-30 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Discovery of regulatory T cells programmed to suppress immune responses
WO2014052545A2 (en) 2012-09-28 2014-04-03 Dana-Farber Cancer Institute, Inc. Targeted expansion of qa-1-peptide-specific regulatory cd8 t cells to ameliorate arthritis
AU2013350312B2 (en) * 2012-11-22 2018-03-22 Factor Therapeutics Limited Complex-formation-modulating agents and uses therefor
EP3186274B1 (en) * 2014-08-27 2021-10-06 Dana-Farber Cancer Institute, Inc. Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
CN114929742A (en) * 2019-11-26 2022-08-19 万能溶剂有限公司 Methods and compositions for treating aging-related injuries using modulators of trefoil factor family member 2
CN113092757B (en) * 2021-02-23 2024-02-06 承德医学院 Early diagnosis kit for liver metastasis of lung cancer and preparation and use methods thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002025285A1 (en) * 2000-09-20 2002-03-28 The University Of Liverpool Prognostic indicator
EP1413313A1 (en) * 2001-06-27 2004-04-28 Meiji Seika Kaisha Ltd. DIAGNOSIS AND TREATMENT OF INSULIN−DEPENDENT DIABETES MELLITUS AND INSULITIS
US20040157253A1 (en) * 2003-02-07 2004-08-12 Millennium Pharmaceuticals, Inc. Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002025285A1 (en) * 2000-09-20 2002-03-28 The University Of Liverpool Prognostic indicator
EP1413313A1 (en) * 2001-06-27 2004-04-28 Meiji Seika Kaisha Ltd. DIAGNOSIS AND TREATMENT OF INSULIN−DEPENDENT DIABETES MELLITUS AND INSULITIS
US20040157253A1 (en) * 2003-02-07 2004-08-12 Millennium Pharmaceuticals, Inc. Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ASHKAR SAMY ET AL: "Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 287, no. 5454, 4 February 2000 (2000-02-04), pages 860 - 864, XP002161278, ISSN: 0036-8075 *
ASPORD CAROLINE ET AL: "Early events in islets and pancreatic lymph nodes in autoimmune diabetes.", JOURNAL OF AUTOIMMUNITY. AUG 2004, vol. 23, no. 1, August 2004 (2004-08-01), pages 27 - 35, XP002396385, ISSN: 0896-8411 *
FRANKE ET AL: "Developments in the prediction of type 1 diabetes mellitus, with special reference to insulin antibodies", DIABETES/METABOLISM RESEARCH AND REVIEWS, WILEY, LONDON,, GB, vol. 21, 2005, pages 395 - 415, XP002419953, ISSN: 1520-7552 *
MELANITOU EVIE: "Functional genomics in early autoimmunity.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. JUN 2005, vol. 1050, June 2005 (2005-06-01), pages 64 - 72, XP002396386, ISSN: 0077-8923 *
VUKKADAPU SANKARANAND S ET AL: "Dynamic interaction between T cell-mediated beta-cell damage and beta-cell repair in the run up to autoimmune diabetes of the NOD mouse", PHYSIOLOGICAL GENOMICS, vol. 21, no. 2, April 2005 (2005-04-01), pages 201 - 211, XP002396387, ISSN: 1094-8341 *
YU LIPING ET AL: "Early expression of antiinsulin autoantibodies of humans and the NOD mouse: Evidence for early determination of subsequent diabetes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 97, no. 4, 15 February 2000 (2000-02-15), pages 1701 - 1706, XP002444542, ISSN: 0027-8424 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8052964B2 (en) 2002-09-09 2011-11-08 Hanall Biopharma Co., Ltd. Interferon-β mutants with increased anti-proliferative activity
US8057787B2 (en) 2002-09-09 2011-11-15 Hanall Biopharma Co., Ltd. Protease resistant modified interferon-beta polypeptides
US8105573B2 (en) 2002-09-09 2012-01-31 Hanall Biopharma Co., Ltd. Protease resistant modified IFN beta polypeptides and their use in treating diseases
US8114839B2 (en) 2002-09-09 2012-02-14 Hanall Biopharma Co., Ltd. Protease resistant modified erythropoietin polypeptides
US7884073B2 (en) 2004-11-04 2011-02-08 Hanall Biopharma Co., Ltd. Modified growth hormone
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones

Also Published As

Publication number Publication date
WO2007110230A2 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
WO2007110230A3 (en) Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
Blackburn et al. Bi-allelic alterations in AEBP1 lead to defective collagen assembly and connective tissue structure resulting in a variant of Ehlers-Danlos syndrome
Atiakshin et al. Characterization of mast cell populations using different methods for their identification
Harbour et al. The cargo-selective retromer complex is a recruiting hub for protein complexes that regulate endosomal tubule dynamics
ES2777948T3 (en) Biochemical markers for CVD risk assessment
Lee et al. Detection of hydroxyapatite in calcified cardiovascular tissues
Moore et al. Simultaneous measurement of cell cycle and apoptotic cell death
Laman et al. Significance of peptidoglycan, a proinflammatory bacterial antigen in atherosclerotic arteries and its association with vulnerable plaques
KR100475642B1 (en) A method for the diagnosis of cancers by measuring the changes of glycosylation of proteins related to tumorigenesis and metastasis and kit for diagnosis of cancers using the same
ES2538504T3 (en) Urine markers for bladder cancer detection
WO2009126969A3 (en) Biomarkers for endometrial disease
WO2004058044A3 (en) Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
KR20080063326A (en) Atopic dermatitis marker and technique of using the same
JPH09505894A (en) Method for detecting and / or optionally quantifying and / or separating dead cells in or from a sample
JP4279677B2 (en) Use of aldose 1-epimerase (mutarotase) for diagnosis and treatment of inflammatory diseases and sepsis
AUPS293002A0 (en) Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
KR20150036111A (en) Bag3 as biochemical serum and tissue marker
Chernyaeva et al. Reduced binding of apoE4 to complement factor H promotes amyloid‐β oligomerization and neuroinflammation
Risseeuw et al. Bruch's membrane calcification in pseudoxanthoma elasticum: comparing histopathology and clinical imaging
ES2288358B1 (en) FIBROSIS MARKERS.
US20040028684A1 (en) Cancer diagnosis and assays for screening anti-cancer agents
WO2003069349A3 (en) Method for diagnosis of inflammatory diseases using mrp8/mrp14
JP2020510423A (en) Biomarker
Pan et al. Elevation of serum CXC chemokine ligand-12 levels predicts poor outcome after aneurysmal subarachnoid hemorrhage
RU2360924C1 (en) Marker of prostate gland cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07723645

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007723645

Country of ref document: EP

122 Ep: pct application non-entry in european phase

Ref document number: 07723645

Country of ref document: EP

Kind code of ref document: A2